EE200300485A - Tiohüdantoinid ja nende kasutamine diabeedi raviks - Google Patents

Tiohüdantoinid ja nende kasutamine diabeedi raviks

Info

Publication number
EE200300485A
EE200300485A EEP200300485A EEP200300485A EE200300485A EE 200300485 A EE200300485 A EE 200300485A EE P200300485 A EEP200300485 A EE P200300485A EE P200300485 A EEP200300485 A EE P200300485A EE 200300485 A EE200300485 A EE 200300485A
Authority
EE
Estonia
Prior art keywords
thiohydantoin
diabetes
treatment
Prior art date
Application number
EEP200300485A
Other languages
English (en)
Estonian (et)
Inventor
Boubia Benassa
Chaput Evelyne
Ou Khan
Ratel Philippe
Original Assignee
Laboratoires Fournier S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Fournier S.A. filed Critical Laboratoires Fournier S.A.
Publication of EE200300485A publication Critical patent/EE200300485A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300485A 2001-04-04 2002-04-04 Tiohüdantoinid ja nende kasutamine diabeedi raviks EE200300485A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104552A FR2823209B1 (fr) 2001-04-04 2001-04-04 Nouvelles thiohydantoines et leur utilisation en therapeutique
PCT/FR2002/001167 WO2002081453A1 (fr) 2001-04-04 2002-04-04 Hiohydantoïnes et leur utilisation dans le traitement du diabete

Publications (1)

Publication Number Publication Date
EE200300485A true EE200300485A (et) 2004-02-16

Family

ID=8861916

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300485A EE200300485A (et) 2001-04-04 2002-04-04 Tiohüdantoinid ja nende kasutamine diabeedi raviks

Country Status (21)

Country Link
US (1) US20040116417A1 (cs)
EP (1) EP1373219A1 (cs)
JP (1) JP2004525175A (cs)
KR (1) KR20030085565A (cs)
CN (1) CN1500081A (cs)
BG (1) BG108225A (cs)
BR (1) BR0207910A (cs)
CA (1) CA2444024A1 (cs)
CZ (1) CZ20032696A3 (cs)
EE (1) EE200300485A (cs)
FR (1) FR2823209B1 (cs)
HU (1) HUP0401537A3 (cs)
IL (1) IL158195A0 (cs)
MX (1) MXPA03009083A (cs)
NO (1) NO20034430L (cs)
PL (1) PL364904A1 (cs)
RU (1) RU2003129532A (cs)
SK (1) SK12332003A3 (cs)
WO (1) WO2002081453A1 (cs)
YU (1) YU75903A (cs)
ZA (1) ZA200307372B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
CA2493458A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
ITMI20022748A1 (it) * 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
SG145700A1 (en) * 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Pyridyl derivatives and their use as therapeutic agents
AR047557A1 (es) 2003-07-30 2006-01-25 Xenon Pharmaceuticals Inc Compuestos derivados de piridazina y su uso como agentes terapeuticos
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005099693A2 (en) * 2004-02-24 2005-10-27 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
DE102004024011A1 (de) * 2004-05-14 2005-12-01 Bayer Chemicals Ag Difluorbenzo-1,3-dioxole
TW200626153A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
BRPI0515489A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
EP2266569A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP4958785B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
TW200626148A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7777036B2 (en) * 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2007243651C1 (en) * 2006-03-27 2013-03-14 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP2013187B1 (en) 2006-03-29 2014-10-29 The Regents of The University of California Diarylthiohydantoin compounds
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
US7538107B2 (en) 2006-08-15 2009-05-26 Wyeth Oxazinan-2-one derivatives useful as PR modulators
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
RU2490257C2 (ru) 2008-05-30 2013-08-20 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CN106983749A (zh) 2010-02-16 2017-07-28 亚拉冈制药公司 雄激素受体调节剂及其用途
EP2538785B1 (en) * 2010-02-24 2018-03-21 Medivation Prostate Therapeutics LLC Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
WO2013067142A1 (en) * 2011-11-02 2013-05-10 Medivation Technologies, Inc. Compounds and treatment methods
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2551134A (en) * 1947-05-15 1951-05-01 Du Pont Process of color developing with 2-thiohydantoin derivatives
US3923994A (en) * 1973-07-13 1975-12-02 Smithkline Corp Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity
GB1472467A (en) * 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
US4473393A (en) * 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
US5821372A (en) * 1995-11-28 1998-10-13 American Home Products Corporation 2-thioxo-imidazolidin-4-one derivatives
US5554607A (en) * 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
NO20034430L (no) 2003-10-06
CA2444024A1 (fr) 2002-10-17
MXPA03009083A (es) 2004-11-22
US20040116417A1 (en) 2004-06-17
WO2002081453A1 (fr) 2002-10-17
PL364904A1 (en) 2004-12-27
RU2003129532A (ru) 2005-04-10
SK12332003A3 (sk) 2004-04-06
ZA200307372B (en) 2004-09-22
IL158195A0 (en) 2004-03-28
NO20034430D0 (no) 2003-10-03
CN1500081A (zh) 2004-05-26
YU75903A (sh) 2006-05-25
CZ20032696A3 (cs) 2003-12-17
JP2004525175A (ja) 2004-08-19
BG108225A (en) 2005-04-30
KR20030085565A (ko) 2003-11-05
WO2002081453A8 (fr) 2002-11-14
FR2823209A1 (fr) 2002-10-11
BR0207910A (pt) 2004-08-03
FR2823209B1 (fr) 2003-12-12
HUP0401537A3 (en) 2005-06-28
HUP0401537A2 (hu) 2005-01-28
EP1373219A1 (fr) 2004-01-02

Similar Documents

Publication Publication Date Title
EE200300485A (et) Tiohüdantoinid ja nende kasutamine diabeedi raviks
DE122009000014I1 (de) Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
EE05073B1 (et) Retigabiin kasutamiseks neuropaatilise valu ravis
EE05516B1 (et) Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
IL160917A0 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
DK1411064T3 (da) Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE200300545A (et) 4-(fenüülpiperasinüülmetüül)bensamiidi derivaadid, nende valmistamine ja kasutamine valu, ärevuse ja seedetrakti häirete ravis
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
EE200300473A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
EE200300474A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
DE60223576D1 (de) Hautbehandlungszusammensetzung
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
PL356784A1 (pl) Substancja do zastosowania w leczeniu łuszczycy
PL357827A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
EE200300540A (et) 4-(fenüülpiperidiin-4-ülideenmetüül)bensamiidi derivaadid, nende valmistamine ja kasutamine valu, ärevuse või seedetrakti häirete ravis
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
EP1567556A4 (en) RECOMBINANT IMMUNOTOXIN AND USE IN THE TREATMENT OF TUMORS
DE60216376D1 (de) Verbundklebstoff und dessen Verwendung
EE200300527A (et) 4-(fenüülpiperidiin-4-ülideenmetüül)bensamiidi derivaadid ja nende kasutamine valu, ärevuse või seedetrakti häirete raviks
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
FI20010410L (fi) Mukaanottaja ja lukituslaite
EE200300542A (et) 4-(fenüülpiperidiin-4-ülideenmetüül)bensamiidi derivaadid, nende valmistamine ja kasutamine valu, ärevuse või seedetrakti häirete ravis